Results 231 to 240 of about 214,611 (264)

Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study. [PDF]

Cancer Manag Res
Ying J, Wang Z, Wang J, Xia M.
europepmc   +1 more source

Pretreatment Prediction of Tumor Recurrence in Breast Cancer After Neoadjuvant Systemic Therapy Using Machine Learning With Clinical and CT Radiomics Features

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to develop machine learning models for predicting tumor recurrence in breast cancer before neoadjuvant systemic therapy (NST) by integrating clinical and radiomic features derived from pretreatment computed tomography (CT).
Huei‐Yi Tsai, Jo‐Ching Wang, Wei‐Shiuan Chung, Jui‐Sheng Hsu, Shu‐Yen Lin, Ming‐Feng Hou, Ming‐Chung Chou   +6 more
wiley   +1 more source

Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2- Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy: Outcomes from a Multidisciplinary Workshop in India. [PDF]

Breast Cancer (Dove Med Press)
Mallavarapu KM, Reddy B R, Sp S, Goyal P, Sathyanarayanan V, Rauthan A, Bajpai J, Bhargava PG, Agarwal M, Pinninti R, Chennamaneni R, Chaitanya P K, Bala SC, Pydi VR, Dev R, Dattatreya PS, Batra U, K GB, Shetty D, Paul K, Rathi P, Basade M.   +21 more
europepmc   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Clinicopathological characteristics and response to neoadjuvant chemotherapy in HER2-low hormone receptor-positive breast cancer: a retrospective cohort study. [PDF]

Front Oncol
Wu W, Li X, Wei Y, Liu T, Yang Z, Liu X.
europepmc   +1 more source

Clinically actionable genomic alterations in breast cancer brain metastases. [PDF]

ESMO Open
Griguolo G, Collesei A, Lazzarini E, Bottosso M, Dieci MV, Fineberg S, Bauchet L, Landa G, Miglietta F, Jacob J, Rigau V, La Commare M, Trovò L, Fassan M, Jacot W, Dei Tos AP, Indraccolo S, Darlix A, Guarneri V.   +18 more
europepmc   +1 more source

Factors influencing oncologists' decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer. [PDF]

Front Oncol
Li Q, Cambron-Mellott MJ, Xu X, Kashine-Tack N, Hayes JF, Mishkin KE, Gordon A, Will O, Howell LA, Noval A, Beusterien K.   +10 more
europepmc   +1 more source

Computational methods, clinical evidence, and translational readiness for artificial intelligence for HER2 assessment using silver in situ hybridization (SISH). [PDF]

Breast Cancer Res
Badawy W.
europepmc   +1 more source

Low Rates of Discontinuation Unrelated to Disease Progression with Trastuzumab Deruxtecan in Metastatic Breast Cancer: A Real-World Study. [PDF]

Cancers (Basel)
Licata L, Patanè F, Guarino A, Galbardi B, Battaglia A, Mariani M, Zanibelli C, Notini G, Naldini MM, Bosi C, Chiavassa A, Piras M, Persano I, Rognone A, Sica L, Zambelli S, Zucchinelli P, Viale G, Bianchini G.   +18 more
europepmc   +1 more source